Oruka Therapeutics (ORKA) said Monday the US Food and Drug Administration has cleared its investigational new drug application to start the phase 2a trial of ORKA-001 intended for moderate to severe psoriasis.
The company said it aims to enroll about 80 patients under the trial, with a primary endpoint of PASI 100 or completely clear skin.
Oruka Therapeutics said it expects to release efficacy and response duration data from the phase 2a trial in H2 2026.
Shares of Oruka Therapeutics were up more than 7% in recent premarket activity Monday.
Price: 15.60, Change: +1.06, Percent Change: +7.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.